PerkinElmer Expands Into Cell Biology With $260M Nexcelom Bioscience Acquisition

  • PerkinElmer Inc PKI has agreed to acquire privately-held Nexcelom Bioscience, a provider of instruments, workstations, assays, cell reagents & consumables with application in the development of cell and gene and immuno-oncology therapies, virology drugs, and vaccines.
  • The deal value of $260 million will be paid using cash on hand. As of March 31, the company reported cash and equivalents of $988 million.
  • The agreement to acquire Nexcelom comes five months after PerkinElmer added Horizon Discovery, a gene editing, and gene modulation tool provider.
  • Nexcelom has around 130 employees, with expected 2021 revenues of nearly $40 Million.
  • The transaction is expected to close during the second quarter of 2021.
  • PerkinElmer's existing biologics, vaccine, and cell & gene research solutions feature in vivo and cell painting screening technologies; immunoassays; CRISPR, RNAi, DNA tools and custom cell lines; cell plate readers and advanced automation; microfluidics and analytical platforms.
  • Price Action: PKI shares closed at $137.86 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewsHealth CareGeneralBriefsCell Biology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!